TrialInvestigational new drugs2012

Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.

Ajjai Alva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.